Schneeweiss S, Patorno E
Endocr Rev. 2021; 42(5):658-690.
PMID: 33710268
PMC: 8476933.
DOI: 10.1210/endrev/bnab007.
Zhao S, Lyu H, Solomon D, Yoshida K
Ann Rheum Dis. 2020; 79(7):883-890.
PMID: 32381560
PMC: 8693471.
DOI: 10.1136/annrheumdis-2020-217200.
Simon T, Boers M, Hochberg M, Baker N, Skovron M, Ray N
Arthritis Res Ther. 2019; 21(1):228.
PMID: 31703717
PMC: 6839238.
DOI: 10.1186/s13075-019-1992-x.
Xu Z, Xu P, Fan W, Yang G, Wang J, Cheng Q
Exp Ther Med. 2017; 14(4):3491-3500.
PMID: 29042938
PMC: 5639314.
DOI: 10.3892/etm.2017.5003.
Beukelman T, Kimura Y, Ilowite N, Mieszkalski K, Natter M, Burrell G
Pediatr Rheumatol Online J. 2017; 15(1):30.
PMID: 28416023
PMC: 5392971.
DOI: 10.1186/s12969-017-0160-6.
The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis.
Beukelman T, Xie F, Baddley J, Chen L, Mannion M, Saag K
Arthritis Res Ther. 2016; 18(1):210.
PMID: 27655411
PMC: 5032246.
DOI: 10.1186/s13075-016-1109-8.
Comparative Rates of Serious Infections Among Patients With Systemic Lupus Erythematosus Receiving Immunosuppressive Medications.
Feldman C, Marty F, Winkelmayer W, Guan H, Franklin J, Solomon D
Arthritis Rheumatol. 2016; 69(2):387-397.
PMID: 27589220
PMC: 5274610.
DOI: 10.1002/art.39849.
Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.
Desai R, Solomon D, Schneeweiss S, Danaei G, Liao K, Kim S
Epidemiology. 2016; 27(3):414-22.
PMID: 26808597
PMC: 5497216.
DOI: 10.1097/EDE.0000000000000446.
Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus.
Feldman C, Yazdany J, Guan H, Solomon D, Costenbader K
Arthritis Care Res (Hoboken). 2015; 67(12):1712-21.
PMID: 26097166
PMC: 4684806.
DOI: 10.1002/acr.22636.
Staphylococcus aureus sepsis in rheumatoid arthritis.
Sams M, Olsen M, Joshi R, Ranganathan P
Rheumatol Int. 2015; 35(9):1503-10.
PMID: 25758228
DOI: 10.1007/s00296-015-3239-8.
TNF- Antagonist and Infection in Rheumatoid Arthritis.
Simard J, Mittleman M, Shadick N, Karlson E
Open J Rheumatol Autoimmune Dis. 2014; 2(2):14-20.
PMID: 25019035
PMC: 4089359.
DOI: 10.4236/ojra.2012.22004.
Effect of evidence-based drug therapy on long-term outcomes in patients discharged after myocardial infarction: a nested case–control study in Italy.
Kirchmayer U, Di Martino M, Agabiti N, Bauleo L, Fusco D, Belleudi V
Pharmacoepidemiol Drug Saf. 2013; 22(6):649-57.
PMID: 23529919
PMC: 3746119.
DOI: 10.1002/pds.3430.
Biologic response modifiers to decrease inflammation: Focus on infection risks.
Le Saux N
Paediatr Child Health. 2013; 17(3):147-54.
PMID: 23449972
PMC: 3287096.
DOI: 10.1093/pch/17.3.147.
Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.
Beukelman T, Xie F, Chen L, Baddley J, Delzell E, Grijalva C
Arthritis Rheum. 2012; 64(8):2773-80.
PMID: 22569881
PMC: 3409300.
DOI: 10.1002/art.34458.
Initiation of tumor necrosis factor-α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases.
Grijalva C, Chen L, Delzell E, Baddley J, Beukelman T, Winthrop K
JAMA. 2011; 306(21):2331-9.
PMID: 22056398
PMC: 3428224.
DOI: 10.1001/jama.2011.1692.
A basic study design for expedited safety signal evaluation based on electronic healthcare data.
Schneeweiss S
Pharmacoepidemiol Drug Saf. 2010; 19(8):858-68.
PMID: 20681003
PMC: 2917262.
DOI: 10.1002/pds.1926.
Initiation of rheumatoid arthritis treatments and the risk of serious infections.
Grijalva C, Kaltenbach L, Arbogast P, Mitchel Jr E, Griffin M
Rheumatology (Oxford). 2009; 49(1):82-90.
PMID: 19906833
PMC: 2909794.
DOI: 10.1093/rheumatology/kep325.
